Pharmaceuticals
Collaboration with pharmaceutical companies is a significant part of our mission.
Those are at the forefront of research and treatment of MPN and therefore directly impact the lives of all patients.
Our initiatives support the pharmaceutical industry in various aspects.
Swift Synergy
Faster communications and cooperations between industry and the patient community to improve the quality of care and research.
Feedback & Guidance
Provide feedback and guidance on developing and implementing new treatments and clinical trials.
Awareness Boost
Raise awareness and educate about the MPN among health professionals, polycymakers and the public.
MPN Impact
Making a difference in the MPN field, improving MPN patients live.
Patient Testimonials
Giving voice to patients with MPN and shareing their stories and struggles at different phases of their journey and therapy.
MPN Dialogues
We foster engaging discussions on MPN-related topics by hosting and promoting webinars, seminars, and roundtables.
Our MPN Awareness Partners
AOP Health
Targeting Rare Diseases and Critical Care
AOP Health is the European pioneer for integrated therapies for rare diseases and in critical care. AOP Orphan – now AOP Health – was founded in 1996 by Dr. Rudolf Widmann with the aim of developing and providing therapy options for patients with rare diseases, and then introducing the therapy options first in Austria, the European core countries of AOP Health, and finally in the international market. Thanks to our advancements in the field of therapies, an increasing number of patients survive their disease or are able to live with it for a longer period of time. In the next few decades, personalized medicine, individual treatment opportunities will emerge more and more as the standard in AOP Health’s therapy concepts as well.
​
Links:
Bristol Meyers Squibb
Global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
At Bristol Myers Squibb, we believe in the power of science to address some of the most challenging diseases of our time. Our focus on these unmet needs comes during a remarkable time, when unprecedented scientific breakthroughs are advancing the treatment of disease as never before in human history. We work every day to transform patients’ lives through science. Each day, our employees around the world work together for patients – they are at the center of everything we do. They inspire us. They are the reason we come to work each day. We combine the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company powered by talented individuals who drive scientific innovation. We are proud of the advancements we have made in oncology, hematology, immunology and cardiovascular disease, and we are dedicated to helping patients prevail over serious diseases through our diverse and promising pipeline and new scientific platforms.
​
As global citizens, we work sustainably and responsibly to create a positive impact in the communities where we live and work. We conduct our global business with the utmost integrity and transparency. We support programs, initiatives and organizations that help improve health, expand research opportunities, promote and expand STEM education and deliver basic human services to our communities.
​
Links:
GSK
We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.
We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.
We aim to positively impact the health of 2.5 billion people over the next 10 years. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance.
We are a company where outstanding people can thrive.
GSK has changed. In July 2022, we demerged our world-leading consumer healthcare business, Haleon. We are now a fully focused biopharma company. We prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We will focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.
​
Links:
-
Website: Home | GSK
-
Source: Company | GSK
Kartos Therapeutics
Dedicated to the development of novel, targeted therapeutics that meaningfully improve the lives of patients with cancer
Kartos Therapeutics is a privately held, clinical-stage biopharmaceutical company developing a potentially best-in-class MDM2 inhibitor. Launched in 2018 by proven industry veterans, we are a passionate team based in Redwood City, California, and Bellevue, Washington.
​
We have brought together scientists and clinicians with a deep understanding of hematology and oncology and an experienced leadership team. Together, we’re building an exciting biotechnology company with a culture defined by caring, ambition, dedication, and teamwork!
​
Links:
-
Website: Home | Kartos Therapeutics
-
Source: About | Kartos Therapeutics
Karyopharm Therapeutics
​Karyopharm is an innovation-driven pharmaceutical company whose core technology leverages the inhibition of nuclear export as a mechanism to treat patients with cancer and other medical conditions.
At Karyopharm, we are dedicated to improving the lives of patients and their loved ones through the development of groundbreaking therapies for cancer and other rare diseases. Achieving this life-changing work demands a team that thrives on innovation and collaboration.
Therefore, we seek out a wide range of backgrounds and experiences in candidates, knowing that diverse perspectives spark the creativity and problem-solving needed to deliver the best outcomes for our patients. Once individuals join our team, we ensure they feel valued, supported, and empowered in a safe environment that unlocks their full potential.
By prioritizing the Inclusion & Wellness of our employees, we strengthen our organization and ensure our collective success, ultimately enhancing the care we provide to patients, families, and physicians.
​
Links:
-
Website: Home - Karyopharm (karyoparhm.com)
-
Source: About Karyopharm - Karyopharm (karyoparhm.com)
Mitsubishi Tanabe Pharma
Mitsubishi Tanabe Pharma Historical Museum About Us Be a healthcare company that delivers optimal therapy to each individual.
Mitsubishi Tanabe Pharma Corporation es una empresa farmacéutica japonesa de Osaka, una subsidiaria de Mitsubishi Chemical Holdings Corporation . Mitsubishi Pharma Corporationse formó en 2001 a partir de la fusión de Mitsubishi-Tokyo Pharmaceuticals y Welfide Corporation. El 1 de octubre de 2007, Tanabe Seiyaku Co., Ltd. se fusionó con Mitsubishi Pharma para formar Mitsubishi Tanabe Pharma.
​
Fundada originalmente en 1678, Mitsubishi Tanabe se considera una de las compañías farmacéuticas más antiguas del mundo. Mitsubishi Tanabe Pharma es miembro del grupo financiero Mitsubishi UFJ Financial Group (MUFJ) keiretsu .
​
Links:
MSD
We use the power of leading-edge science to save and improve lives around the world
For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.
Merck has acquired Imago BioSciences, a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases. Merck’s acquisition of Imago augments its pipeline and strengthens its presence in the growing field of hematology.
​
Links:
-
Website: MSD | Home
-
Source: Merck to Acquire Imago BioSciences, Inc. - Merck.com
Novartis
Novartis is a science-driven global pharmaceutical company focused on pioneering innovative medicines to improve and extend the lives of people worldwide, leveraging advanced technologies and data science to transform the treatment of serious diseases.
At Novartis, we are driven by a powerful purpose: to reimagine medicine and improve the lives of people around the world. Through cutting-edge science and a deep commitment to innovation, we develop transformative therapies that address some of the most serious and challenging health conditions of our time.
​
We believe that the key to achieving these breakthroughs lies in the strength of our people. That’s why we actively seek individuals from a wide range of backgrounds, experiences, and perspectives—because diversity fuels our creativity, accelerates innovation, and enables us to better understand and serve the needs of patients globally.
Once part of our team, we are committed to fostering an inclusive, collaborative, and supportive environment where everyone can thrive. We empower our associates with the tools, flexibility, and opportunities to grow—personally and professionally—while ensuring their well-being remains a top priority.
​
By championing inclusion, curiosity, and a culture of continuous learning, we strengthen our ability to tackle complex challenges and deliver meaningful impact—advancing science, transforming care, and ultimately, touching millions of lives across the world.
​
Links:
-
Website: Home - Novartis (novartis.com)
-
Source: About Novartis - Novartis (novartis.com)
Silence Therapeutics
Silence Therapeutics is a biotechnology company focused on developing precision medicines using RNA interference (RNAi) to selectively silence disease-associated genes, with the goal of transforming the treatment of serious and rare genetic conditions.
At Silence Therapeutics, we are committed to transforming the lives of patients by developing innovative RNA interference (RNAi) therapies that target and silence the genes at the root of serious diseases. Our precision-based approach allows us to design medicines that are both highly specific and effective, with the potential to change the treatment landscape for rare and underserved conditions.
​
Our mission is powered by a diverse and passionate team of scientists, clinicians, and professionals who are united by curiosity, purpose, and a drive to make a real difference. We believe that innovation thrives in an environment of inclusion, collaboration, and mutual respect—where every voice is heard, and every idea has the potential to lead to breakthrough science.
​
We actively foster a culture that values well-being, personal growth, and shared success. By empowering our people and investing in a supportive and dynamic workplace, we enable them to reach their full potential while staying focused on what matters most: bringing life-changing therapies to patients who need them.
Through science, integrity, and commitment, we aim to redefine what’s possible in genetic medicine—one silenced gene at a time.
​
Links:
-
Website: Home - Silence Therapeutic (https://silence-therapeutics.com)
-
Source: About Silence Therapeutic - Silence Therapeutic (https://silence-therapeutics.com)
Protagonist Therapeutics
We strive to improve patients’ lives through the power of peptide drug discovery and development, targeting areas of unmet need across rare and prevalent diseases where treatments are limited or inadequate.
Welcome to Protagonist, a clinical-stage biopharmaceutical company poised to deliver life-changing therapies. At Protagonist, we strive to improve patients’ lives through the power of drug discovery and development, targeting areas of unmet need across rare and prevalent diseases where treatments are limited or inadequate. Protagonist is a clinical-stage biopharmaceutical company committed to developing novel peptide-based drugs to address significant unmet medical needs and making them available broadly to patients as quickly as possible by conducting the clinical trials necessary to gain approval by regulatory authorities. We have five novel peptidic assets currently in different stages of clinical studies. Rusfertide (PTG-300) is a hepcidin mimetic currently being studied as a treatment for polycythemia vera (PV) and hereditary hemochromatosis (HH). PN-943 is an α4β7 integrin-specific antagonist being studied in patients with moderate-to-severely active ulcerative colitis (UC). In October 2020, we announced the selection of two second-generation IL-R antagonists for advancement into clinical development, PN-235 (also referenced as JNJ-77242113) and PN-232 (also referenced as JNJ-75105186)
​
Links:
Opinion Health
Quality Research Solutions
Opinion Health is a research company that helps organizations in planning, implementing and executing strategic healthcare business decisions by putting patients and key healthcare stakeholders at the core of research. They have more than 50 years of experience conducting market research around the globe for major pharmaceutical and healthcare companies. They provide their clients with actionable, cost-effective and quality input to their strategy, marketing and product decisions. They have on-staff medical advisers and a multi-lingual and multi-cultural team. They have built panels of patients suffering from both high and some very low prevalence diseases and added these to their panels of healthcare professionals and other decision makers. They use primary and secondary research and investigation methods to resolve any problems related to multi-disciplinary teams. They have developed their Social Media Disease Monitor which allows clients to measure the pulse of their current and target patients and what they are saying about their and their competitors’ products. They form a true partnership with their clients from initial discussions about a potential project through to the final delivery of the findings and their integration into action plans.
​
Links:
-
Website: Opinion Health
-
Source: About - Opinion Health